Allogeneic stem cell-derived "repair unit" therapy and the barriers to clinical deployment.
The development of cellular therapies has been seriously hampered by the paucity of cells available for grafting from living or cadaver donors. This sourcing problem can be resolved, at least in theory, by generating tissue-specific cells from autologous or allogeneic stem cells. Nonetheless, there are formidable barriers to the use of stem cells in the clinic. This review focuses on identifying and surmounting these barriers.
Strom
Terry B
TB
Department of Medicine, Harvard Medical School, and Division of Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. tstrom@caregroup.harvard.edu
Field
Loren J
LJ
Ruediger
Manfred
M
D000818:Animals; D006801:Humans; D007668:Kidney / Q000502:physiology*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D012038:Regeneration; D033581:Stem Cell Transplantation / Q000379:methods* / Q000639:trends*